Background illustration for clinical trials search

Paid Clinical Trials Tuscaloosa

Discover 870 paid clinical trials in Tuscaloosa, Alabama. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

for
Non-small Cell Lung Cancer
Location: Birmingham AL, Marietta GA, Nashville TN, Knoxville TN,
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT06712316

Phase 2, Phase 3, Recruiting

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

for
Breast Cancer, TNBC - Triple-Negative Breast Cancer,
Location: Birmingham AL, Nashville TN, Carbondale IL, O'Fallon IL,
Sponsor: Tempus AI

Sex: All

Age: 18 - 70+

Code: NCT07211178

Recruiting

Retinal Detachment Prevention (Laser Prophylaxis) in Stickler Syndrome (SS)

for
Stickler Syndrome Type 1, Stickler Syndrome Type 2
Location: Birmingham AL, Nashville TN, Royal Oak MI, Rochester MN,
Sponsor: Helen Keller Eye Research Foundation

Sex: All

Age: 0+

Code: NCT07146516

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for
Anatomic Stage II Breast Cancer AJCC v8,
Location: Birmingham AL, Columbus MS, New Albany MS, Grenada MS,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06058377

Phase 3, Recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for
Fallopian Tube Endometrioid Adenocarcinoma,
Location: Birmingham AL, Atlanta GA, Pensacola FL, New Orleans LA,
Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06580314

Phase 3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

for
Migraine
Location: Birmingham AL, Ridgeland MS, Mobile AL, Marietta GA,
Sponsor: Kallyope Inc.

Sex: All

Age: 18 - 70+

Code: NCT07645924

Phase 3, Recruiting

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

for
Type 2 Diabetes
Location: Birmingham AL, Columbus GA, Cordele GA, Winter Park FL,
Sponsor: Biomea Fusion Inc.

Sex: All

Age: 18 - 70+

Code: NCT07502508

Phase 2, Recruiting

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

for
Acute Migraine
Location: Birmingham AL, Ridgeland MS, Mobile AL, Marietta GA,
Sponsor: Kallyope Inc.

Sex: All

Age: 18+

Code: NCT07674654

Phase 3, Recruiting

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

for
Chronic Inflammatory Demyelinating Polyneuropathy
Location: Birmingham AL, Nashville TN, Edwardsville IL,
Sponsor: Dianthus Therapeutics

Sex: All

Age: 18 - 70+

Code: NCT06858579

Phase 3, Recruiting

A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

for
Alpha 1-Antitrypsin Deficiency
Location: Birmingham AL, Charleston SC, Boston MA
Sponsor: Beam Therapeutics Inc.

Sex: All

Age: 18 - 70+

Code: NCT06389877

Phase 1, Phase 2, Recruiting

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

for
Peripheral Arterial Disease
Location: Birmingham AL, Jackson TN, Jefferson City TN,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07223593

Phase 3, Recruiting

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

for
High Risk Cardiovascular Disease, Hypertension,
Location: Birmingham AL, Tupelo MS, Sheffield AL, Huntsville AL,
Sponsor: Alnylam Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07181109

Phase 3, Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

for
Locally Advanced / Metastatic Solid Tumors
Location: Birmingham AL, Nashville TN, Orlando FL, Sarasota FL,
Sponsor: Crescent Biopharma, Inc.

Sex: All

Age: 18+

Code: NCT07335497

Phase 1, Phase 2, Recruiting

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

for
Acute Hepatic Porphyria
Location: Birmingham AL, Galveston TX, Oklahoma City OK,
Sponsor: Alnylam Pharmaceuticals

Sex: All

Age: 12+

Code: NCT04883905

Recruiting

Bucillamine Phase 2 Trial in Patients With Cystinuria

for
Cystinuria
Location: Birmingham AL, Madison WI, New York NY, Warwick RI,
Sponsor: Revive Therapeutics, Ltd.

Sex: All

Age: 18 - 70+

Code: NCT02942420

Phase 2, Recruiting

Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention

for
HIV Seropositivity
Location: Birmingham AL, Huntsville AL, Chicago IL
Sponsor: University of Chicago

Sex: All

Age: 18 - 49

Code: NCT05723653

Recruiting

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

for
HIV Infections
Location: Birmingham AL, Atlanta GA, Pensacola FL, Nashville TN,
Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT07473778

Recruiting

A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies

for
HIV
Location: Birmingham AL, Atlanta GA, Boston MA, Seattle WA
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Sex: All

Age: 18 - 60

Code: NCT07569029

Phase 1, Recruiting

A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1

for
HIV
Location: Birmingham AL, Nashville TN, Houston TX,
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Sex: All

Age: 18 - 55

Code: NCT07390955

Phase 1, Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

for
Hormone Receptor Positive HER-2 Negative Breast Cancer,
Location: Birmingham AL, Atlanta GA, Nashville TN, St Louis MO,
Sponsor: Puma Biotechnology, Inc.

Sex: All

Age: 18+

Code: NCT06369285

Phase 2, Recruiting